Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non–Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial

BACKGROUND: Sunitinib and everolimus are standard first-line and second-line therapies, respectively, in clear cell renal cell carcinoma (ccRCC). OBJECTIVE: To conduct a randomized phase 2 trial comparing sunitinib and everolimus in non–clear cell RCC (non-ccRCC). DESIGN, SETTING, AND PARTICIPANTS:...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Eur Urol
Egile Nagusiak: Tannir, Nizar M., Jonasch, Eric, Albiges, Laurence, Altinmakas, Emre, Ng, Chaan S., Matin, Surena F., Wang, Xuemei, Qiao, Wei, Lim, Zita Dubauskas, Tamboli, Pheroze, Rao, Priya, Sircar, Kanishka, Karam, Jose A., McDermott, David F., Wood, Christopher G., Choueiri, Toni K.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2015
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4879109/
https://ncbi.nlm.nih.gov/pubmed/26626617
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2015.10.049
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak